PISCATAWAY, N.J. — Camber Pharmaceuticals has expanded its injectable product portfolio by launching Cisatracurium [sis-AT-ra-KURE-ee-um] Besylate Injection, USP, a generic version of Nimbex®.
The nondepolarizing neuromuscular blocking agent is indicated as an adjunct to general anesthesia to facilitate tracheal intubation in adults and pediatric patients ages 1 month to 12 years. It is also used to provide skeletal muscle relaxation during surgery in pediatric patients ages 2 to 12 years and for mechanical ventilation in adult intensive care unit patients.
The product is available in three presentations:
- 10 mg/5 mL (2 mg/mL), supplied as 10 x 5 mL single-dose vials
- 200 mg/20 mL (10 mg/mL), supplied as 10 x 20 mL single-dose vials
- 20 mg/10 mL (2 mg/mL), supplied as 10 x 10 mL multiple-dose vials
The company noted that its single-dose vials are benzyl alcohol- and preservative-free.
To learn more about Cisatracurium Besylate Injection Single-dose Vials, click here.
To learn more about Cisatracurium Besylate Injection Multiple-dose Vials, click here.
The launch expands Camber’s portfolio of hospital and acute care products and gives healthcare providers additional access to a widely used neuromuscular blocking agent for anesthesia and critical care.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release
